Camel-IDS, VUB spin-off and a private, clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, today announces the launch of a new corporate identity and company name change to PRECIRIX®, effective immediately. Further, the company announces it has received Investigational New Drug (IND) approval to initiate a Phase I/II clinical trial with CAM-H2 in patients with advanced/metastatic HER2-positive breast and gastric cancer.
Ruth Devenyns, CEO of Precirix, commented: “The significant progress in the development of our company, such as the IND approval for CAM-H2, has lead us to adopt a new corporate identity. Precirix reflects our mission to become a leader in precision radiopharmaceuticals as we aim to improve and extend the lives of patients with hard-to-treat cancers.”
pdf file20200921 Precirix - Camel-IDS PR.pdf (63 KB)
